Supernus Pharmaceuticals, Inc. (SUPN) · Oct 19, 2026 · Other events

Supernus Q3 earnings date set as Indivior merger reshapes story

No new info

Supernus scheduled its Q3 earnings release for October 29. The notice confirms timing, but adds no new financial or operational information.

Supernus is expanding from a specialty CNS drugmaker into a broader neuroscience platform after acquiring Sage and agreeing to merge with Indivior, making the upcoming quarter a useful test of commercial execution and integration. The company’s portfolio now spans ADHD, Parkinson’s disease, postpartum depression, epilepsy and other CNS conditions.

This filing only schedules the next information event. Supernus said it will report third-quarter 2026 financial and business results after the market closes on October 29, followed by a 4:30 p.m. Eastern conference call. 〔0〕

There is no earnings read yet. The filing contains no revenue, profit, prescription, product, pipeline, merger, or guidance update, so it cannot support a beat, miss, or change to the standing business story. The meaningful information will arrive with the results, particularly how the Sage products are contributing and whether management provides any update relevant to the pending Indivior combination.

Bottom line: This is a routine calendar notice, not a business development. The real catalyst is Supernus’s October 29 results and management discussion, not today’s filing itself.

What to watch next

Q3 results and business update, October 29

Original filing on SEC EDGAR

More Supernus Pharmaceuticals, Inc. news

Supernus Q3 earnings date set as Indivior merger reshapes story | SUPN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.